
Novartis AG (NVS) – Efficiency in use of profits, is attractive for investors
in Company Report , Healthcare & Life Sciences , Pharma & Biotech on August 29, 2022This report is useful for M&A and business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for insights on any specific sector/industry and market recommendations.
Novartis AG (NVS)
NVS has a high pay-out ratio as compared to other companies in the industry. The company invests very less profits back into the business. This clearly indicate that it is able to achieve growth despite returning most of the profits to the shareholders.
Highlights
Valuation
– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– DCF Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum
Actual & Historical Performance
– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Developments
– M&A Deals
• Peer Performance
– Summary
– Profitability
– Growth
– Price Performance
Ownership
Stock Price Performance
CrispIdea Coverage
No of Pages : 33